anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Percutaneous left atrial appendage occlusion (LAAO) is traditionally performed under general anesthesia with trans-esophageal echocardiography guidance. Intracardiac echo (ICE)-guided LAAO closure is increasing in clinical use. The ICE catheter is crossed into LA via interatrial septum (IAS) after the septum is dilated with LAAO delivery sheath. This step can be time-consuming and requires significant ICE catheter manipulation, which increases the risk of cardiac perforation. Pre-emptive septal balloon dilation can potentially help with ICE advancement in the LA. We sought to evaluate the effect of pre-dilation of the IAS with an 8 mm balloon on the ease of crossing the ICE catheter, fluoroscopy time for crossing, and overall procedure time.
METHODS: The Piedmont LAAO registry was used to identify consecutive patients who underwent LAAO. The initial 25 patients in whom balloon dilation of the IAS was performed served as the experimental cohort, and the 25 consecutive patients before that in whom balloon dilation was not performed served as controls. In the experimental group, after a trans-septal puncture, the sheath was retracted to the right atrium with a guidewire still in the LA. An 8 × 40 mm Evercoss™ over the wire balloon was inflated across the IAS. The ICE catheter was then crossed into the LA using the fluoroscopic landmark of the guide wire and the ICE imaging. The sheath was then advanced along the ICE catheter via the transseptal puncture (TSP) and the procedure continued. Follow-up compputed tomography imaging was obtained at 4-8 weeks.
RESULTS: Each group consisted of 25 patients. There were no significant differences in baseline characteristics. All procedures were performed successfully under conscious sedation and ICE guidance. There was a significant reduction in the overall procedure time, fluoroscopy time, and time for transseptal puncture to ICE in LA. There was no difference in the size of the acute residual interatrial shunt, as measured via ICE, or the size and presence of iatrogenic ASD at follow-up.
CONCLUSION: Balloon dilation of TSP is safe and is associated with increased efficiency in ICE-guided LAAO procedures.
The chemical name of APTIOM (eslicarbazepine acetate) is (S)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. APTIOM is a dibenz[b,f]azepine-5-carboxamide derivative. Its molecular formula is C17H16N2O3 and its molecular weight is 296.32. The chemical structure is: 

APTIOM is a white to off-white, odorless crystalline solid. It is insoluble in hexane, very slightly soluble in aqueous solvents and soluble in organic solvents such as acetone, acetonitrile, and methanol. 

Each APTIOM tablet contains 200 mg, 400 mg, 600 mg or 800 mg of eslicarbazepine acetate and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and povidone.
BACKGROUND: There is a paucity of data comparing periprosthetic hip fracture (PPHFx) outcomes and resource utilization to native fractures. Many surgeons consider periprosthetic hip fractures to be more severe injuries than native fractures. The aim of this systematic review is to characterize the outcomes of PPHFx and assess their severity relative to native hip fractures (NHFx).
METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-Analysis systematic review was conducted using Medline, Biosis, and Cinahl. Primary outcomes were time to surgery, length of stay (LOS), cost of management, disposition, complication rates, readmission rates, and mortality.
RESULTS: 14 articles (13,489 patients) from 2010 to 2018 were included in the study. Study quality was generally low. Patient follow-up ranged from 1 month to 3.2 years. LOS ranged from 5.2 to 38 days. US cost of management was best estimated at $53,669 ± 19,817. Discharge to skilled nursing facilities ranged from 64.5 to 74.5%. Time to surgery ranged from 1.9 to 5.7 days. Readmission rates ranged from 12 to 32%. Per Clavien-Dindo classification, 33.9% suffered minor complications; 14.3% suffered major complications. 1 month and 1 year mortality ranged from 2.9% to 10% and 9.7% to 45%, respectively.
CONCLUSION: Time to surgery and LOS were longer for PPHFx relative to NHFx. Complications' rates were higher for PPHFx compared to NHFx. There is no evidence for differences in LOS, cost, discharge, readmission rates, or mortality between PPHFx and NHFx. These results may serve as a baseline in future evaluation of PPHFx management.
Introduction: Intensive care unit is a special department in the health care facility. Although with highly development of modern medicine nowadays, the average mortality rate in Intensive care unit is still around 7 to 20 %. There are a few tricky problems that intensivists and intensive care nurses faced very often, including intensive care unit delirium, arrythmia and poor digestion problem that will all affect the mortality and morbidity rate of critical care patients. Traditional Chinese Medicine can possibly provide a series of interventions that can alleviate those conditions.

Methods: A randomized control trial will examine the effect of traditional Chinese Medicine interventions vs. routine intensive care unit care. The patients will be randomly divided 1:1 into one of two groups. A total of 80 intensive care patient will have to meet the following criteria: age 20-90, two or less inotropic medicine use. Interventions such as: Chinese herbal medicine decoction, acupuncture, laser acupuncture, Chinese Tuina massage, herbal medicinal cake applied on acupoint, health education and diet education, will be given based on the patients needs and Traditional Chinese Medicine doctor decision. The main outcomes will be the incidence of arrythmia, delirium, and poor digestion and the severity of pain. The investigators will also record intensive care unit mortality, intensive care unit stays and hospital days.
Participants will receive sham tDCS for 20 minutes. The program will be implemented over 12 sessions, occurring three times a week for four weeks.
Stress hyperglycaemia, hypoglycaemia, and diabetes are common in critically ill patients and related to clinical endpoints. To avoid complications related to hypoglycaemia and hyperglycaemia, it is recommended to start insulin therapy for the majority of critically ill patients with persistent blood glucose concentrations higher than 10·0 mmol/L (>180 mg/dL), targeting a range of 7·8-10·0 mmol/L (140-180 mg/dL). However, management and evidence-based targets for blood glucose control are under debate, particularly for patients with diabetes. Recent randomised controlled clinical trials now challenge current recommendations. In this Personal View, we aim to highlight these developments and the important differences between critically ill patients with and without diabetes, taking into account the considerable heterogeneity in this patient group. We critically discuss evidence from prospective randomised controlled trials and observational studies on the safety and efficacy of glycaemic control, specifically in the context of patients with diabetes in intensive care units.
PURPOSE:The titled composition having more improved adhesivity, durability of adhesion state and sustained release properties than well-known pharmaceutical preparations, obtained by adding paste or a thickening agent and a drug to a well-known carboxyvinyl polymer as a base materialf for a dental analgesic. CONSTITUTION:A composition having adhesivity to the interior of oral cavity comprising >=20wt% based on total amount of the composition of carboxyvinyl polymer, 2-50wt% another paste or a thickening agent (e.g., CMC-Na, gum arabic, MC, etc.) and a proper amount of drug. All drugs applicable to the mucosa through the oral cavity may be used as the drug. For example, drugs for central nervous system, deodorants, remedy for stomatitis, etc. may be cited as the drug. This composition is formed into a shape such as a small-sized lamellar form, spherical form, etc. suitable for adhesion to the interior of the oral cavity. A carboxyvinyl polymer is used as a base material for having adhesivity to the interior of the oral cavity, and addition of the thickening agent or paste to it can regulate release and absorption rate of the drug.
Materials and devices are provided for the sensing and manipulation of biomechanical and physiochemical properties of tissues or tissue surfaces. Examples of use include soft tissues such as skin or adipose tissues or more dense tissues such as muscle or heart or dense tissues such as bone. The materials and devices provide for in vivo measurements of biomechanical properties at the tissue surface, e.g. near surface regions of the epidermis or dermis or underlying structures. The devices can be non-invasive and/or non-destructive to the material and, especially for the biomaterials, can be biocompatible and/or biodegradable. The materials and devices can use ultrathin, stretchable networks of mechanical actuators and sensors constructed with nanoribbons of piezoelectric materials.
Accumulating evidence suggests that repeatedly breathing low oxygen levels for brief periods (termed intermittent hypoxia) is a safe and effective treatment strategy to promote meaningful functional recovery in persons with chronic spinal cord injury. Repetitive exposure to mild hypoxia triggers a cascade of events in the spinal cord, including new protein synthesis and increased sensitivity in the circuitry necessary for breathing and walking. Recently, the investigators demonstrated that daily (5 consecutive days) of intermittent hypoxia stimulated walking enhancement in persons with chronic spinal cord injury.

Despite these exciting findings, important clinical questions remain. For example, the investigators do not know if prolonged, but less intense intermittent hypoxia induces longer-lasting motor recovery as has been shown in rat models. The investigators hypothesize that repetitive exposures to modest bouts of low oxygen will enhance and prolong walking recovery in persons with chronic spinal cord injury. The investigators anticipate intermittent hypoxia-induced improvements in overground walking ability, likely due to greater balance in excitatory and inhibitory neural transmission. Whereas excitatory inputs drive walking, inhibitory inputs sculpt and coordinate muscle activity; yet so often remain compromised after chronic injury. Thus, the investigators also predict that repetitive exposures to intermittent hypoxia will result in improved inhibition and subsequently enhance muscle coordination during walking. The investigators will use multiple experimental approaches, including muscle electromyography, measurements of walking dynamics and stretch reflexes. Finally, it is critical to assure that repetitive exposures to intermittent hypoxia do not elicit pathologies characteristic of more severe, chronic hypoxia experienced by individuals with obstructive sleep apnea. The investigators will confirm that repetitive exposure to mild bouts of intermittent hypoxia is safe.
All participants in the core study period, previously treated with risdiplam (nusinersen-naive participants and nusinersen-experienced participants), will receive HD nusinersen, administered as 2 loading doses of 50 milligrams (mg) each, approximately 2 weeks apart, followed by maintenance doses of 28 mg approximately every 4 months. Following the core study period, participants may be given the opportunity to receive maintenance doses of 28 mg nusinersen administered approximately every 4 months up to 2 years during the optional long-term extension (LTE) period.
We have recently described the production of monoclonal antibodies (MAbs) directed against surface antigens of the Candida albicans yeast and mycelial forms, respectively. The mycelial surface antigen recognized by MAb 4E1 was shown to be present predominantly in the terminal third of the hyphal structures. We have now cloned the corresponding gene (CSA1) by MAb 4E1-coated magnetic beads sorting of S. cerevisiae transformants expressing a Candida albicans genomic library. The strategy is both highly selective and sensitive and provides an additional genetic tool to facilitate cloning of Candida genes encoding surface proteins. CSA1 is an intronless single copy gene in Candida and whereas RNA transcripts can be detected in exponentially growing yeast cells, gene expression is strongly increased upon induction of the mycelial growth phase. The deduced amino acid sequence of Csa1p (1203-residues) shares many features with other cell wall proteins including the presence of repetitive motifs and domains. Most strikingly, a Cys-rich hydrophobic domain of 102 amino acids that is repeated five times in the protein shows significant sequence similarity with a major T-cell immunoreactive antigen (Ag2) from another opportunistic fungal human pathogen; Coccidioides immitis. This suggests that Csa1-like proteins may confer unique properties to the cell wall of fungal pathogens.
Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.
This invention relates to the development of agents and methods for treating tumour cells. More particularly, it is concerned with antibodies against the epidermal growth factor receptor (EGFR), which have been found to exhibit an antitumour effect, inducing terminal differentiation in tumour cells, especially those which are characterised by over-expressing EGFR. Included in the invention are these antibodies and their functional equivalents, mutants and derivatives. The antibodies may be murine (rat or mouse), but preferably have framework regions and/or constant regions based on or derived from human antibodies. The present invention also discloses that fragments of these antibodies (eg Fabs) can retain the properties of the complete antibody. The antibodies are useful, e.g. in treating or detecting tumour cells and in targeting therapies.
Long-lasting anti-vascular endothelial growth factor (anti-VEGF) agents have become an option to reduce treatment frequency, with ongoing research exploring optimal responses and safety profiles. This review delves into molecular targets, pharmacological aspects, and strategies for achieving effective and enduring disease control in neovascular age-related macular degeneration (AMD). The molecular pathways involved in macular neovascularization, including angiogenesis and arteriogenesis, are explored. VEGF, PlGF, Ang-1, and Ang-2 play crucial roles in regulating angiogenesis, influencing vessel growth, maturation, and stability. The complex interplay of these factors, along with growth factors like TGFβ and bFGF, contributes to the pathogenesis of neovascular membranes. Current anti-VEGF therapies, including bevacizumab, ranibizumab, aflibercept, brolucizumab, and faricimab, are discussed with a focus on their pharmacokinetics and clinical applications. Strategies to achieve sustained disease control in AMD involve smaller molecules, increased drug dosages, and novel formulations. This narrative review provides a comprehensive overview of the molecular targets and pharmacological aspects of neovascular AMD treatment.
Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia. Monitor patients for these conditions with chronic use.

Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment. Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving corticosteroids already, dosage may have to be increased.

Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Mineralocorticoid supplementation is of particular importance in infancy.

Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.
PURPOSE:To obtain a medicine for prevention and therapy of toxicosis, capable of improving not only metabolic function of liver, etc., for a medicine, etc., but eccritic function for excreting a metabolized medicine, etc. CONSTITUTION:This medicine for prevention and therapy of toxicosis contains 4,7,10,13,16,19-docosahexaenoic acid(DHA), its salt or its derivative. As the DHA derivative, an ester derivative, especially its ethyl ester is preferably used. Absorption of DHA into the living body not only increases the content of DHA as a fatty acid in the blood but allows n-3 series unsaturated fatty acids to constitute the fatty acids in the blood as the main components. It is considered that absorption of DHA has an effect also on other lipids in the blood or other tissues in the living body, e.g. cells. Consequently, the cell membrane is strengthened and the hepatic function is improved.
Pathological aggregation of a specific protein into insoluble aggregates is a common hallmark of various neurodegenerative diseases (NDDs). In the earlier literature, each NDD is characterized by the aggregation of one or two pathogenic proteins, which can serve as disease-specific biomarkers. The aggregation of these specific proteins is thought to be a major cause of or deleterious result in most NDDs. However, accumulating evidence shows that a pathogenic protein can interact and co-aggregate with other pathogenic proteins in different NDDs, thereby contributing to disease onset and progression synergistically. During the past years, more than one type of NDD has been found to co-exist in some individuals, which may increase the complexity and pathogenicity of these diseases. This article reviews and discusses the biochemical characteristics and molecular mechanisms underlying the co-aggregation and co-pathologies associated with TDP-43 pathology. The TDP-43 aggregates, as a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), can often be detected in other NDDs, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and spinocerebellar ataxia type 2 (SCA2). In many cases, TDP-43 is shown to interact and co-aggregate with multiple pathogenic proteins in vitro and in vivo. Furthermore, the co-occurrence and co-aggregation of TDP-43 with other pathogenic proteins have important consequences that may aggravate the diseases. Thus, the current viewpoint that the co-aggregation of TDP-43 with other pathogenic proteins in NDDs and their relevance to disease progression may gain insights into the patho-mechanisms and therapeutic potential of various NDDs.
Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
The present invention provides a breast cancer conditioning convenience food, which uses L- glutamine as the main raw material, is based on the physical characteristics of breast cancer patients, is directed by essence of traditional Chinese medicine theory and has targeted reasonable compatibility: extract of dendrobium, semen coicis, oysters, dandelion, hawthorn, fructus perillae, honeysuckle flower, dates, tangerine red epicarp, longan, date seed, cinnamon, licorice, winter collybia, dried tangerine peel, Poria, siberian solomonseal rhizome, ginseng, gardenia, common selfheal spike, peppermint, appendiculate cremastra pseudobulb and other medicinal and edible herbs. Then vitamins and minerals are added to obtain the food. The food produced according to the formula in the present invention is easy to dissolve, fast to absorb and utilize, and improves the nutritional status of the breast cancer patients. The bioactive components in the medicinal and edible herb extract have assistance effects of improving immunity of human body, thereby playing a role of suppressing cancer and anti-cancer. The food is suitable for breast cancer patients, especially for the cancer patients received radiotherapy or chemotherapy to eat. Therefore, the food has unique advantages of combining triple effects of diet cure, prevention and conditioning.
Semaglutide, a glucagon-like peptide-1 receptor agonist, is clinically used as a glucose-lowering and weight loss medication due to its effects on energy metabolism. In heart failure, energy production is impaired due to altered mitochondrial function and increased glycolysis. However, the impact of semaglutide on cardiomyocyte metabolism under pressure overload remains unclear. Here we demonstrate that semaglutide improves cardiac function and reduces hypertrophy and fibrosis in a mouse model of pressure overload-induced heart failure. Semaglutide preserves mitochondrial structure and function under chronic stress. Metabolomics reveals that semaglutide reduces mitochondrial damage, lipid accumulation, and ATP deficiency by promoting pyruvate entry into the tricarboxylic acid cycle and increasing fatty acid oxidation. Transcriptional analysis shows that semaglutide regulates myocardial energy metabolism through the Creb5/NR4a1 axis in the PI3K/AKT pathway, reducing NR4a1 expression and its translocation to mitochondria. NR4a1 knockdown ameliorates mitochondrial dysfunction and abnormal glucose and lipid metabolism in the heart. These findings suggest that semaglutide may be a therapeutic agent for improving cardiac remodeling by modulating energy metabolism.
Participants will be given a personalised daily exercise target. Participants will be given an activity tracker (a Fitbit ZipTM). The participants will be asked to wear the device all day to monitor their activity. Once a day the participants will be asked to complete the walking target they have been given at completion of their baseline assessment. This target should be completed in one go. The walking programme will last a minimum of 2 weeks and a maximum duration of 4 weeks. The length of time will depend on the length of time between recruitment and when the participant is scheduled to have their surgery.
Stabilized plurilamellar vesicles (SPV) contg. as many as 100 lipid bilayers make up a superior type of liposome for the delivery of drugs in the treatment of such disease as brucellosis of cattle, eye infections, and lymphocytic meningitis of viral origin. Thus, 5 ml of Et2O contg. 100 mg lecithin was placed in a roundbottomed flask, to which was added 0.3 ml of a soln. composed of 100 mg streptomycin in 5-mM HEPES medium (pH = 7.4). The mixt. was sonicated at the same time as it was being evapd. under a N-stream to a viscous paste. Upon resuspension and removal of unencapsulated streptomycin, the resulting SPV were effective against Brucella abortus infection in cattle, B. canis infections in dogs, and kerato conjunctivitis from Mycobacterium bovis infections in lab. animals.